register

News & Trends - MedTech & Diagnostics

First Australian medtech company secures US reimbursement

Health Industry Hub | February 10, 2023 |

MedTech News: A local medical device manufacturer has become the first Australian company to have its medical device receive reimbursement from Centres of Medicare and Medicaid Services (CMS) in the US.

Respiri can now have its patented wheezo device, used for remote patient monitoring (RPM) programs, receive reimbursement in the US.

The RPM program, delivered by Respiri’s partner Access Telehealth, includes patient engagement and remote monitoring using the Access cloud-based platform, Remotli.

“Receiving first reimbursement revenues for wheezo RPM in the US is a major commercialisation milestone for the company,” Respiri CEO Marjan Mikel said.

Although not currently financially material, the company said this event marks a key milestone in the execution of the company’s US business strategy.

Respiri currently generates monthly recurring revenues per patient when the wheezo RPM program is delivered and reimbursed by CMS, in addition to device sales.

“We are also proud to be the first Australian eHealth company whose device has been prescribed by physicians for RPM and successfully reimbursed. We continue to focus our efforts on scaling up operations to engage with and gain acceptance of the wheezo RPM product from both existing and new medical institutions by offering a new standard of care in the US medical industry,” said Mr Mikel.

The wheezo medical device is currently being used by 20 patients across several medical institutions which have engaged with Access Telehealth to use the wheezo RPM program for patients who suffer from respiratory disorders, including asthma and chronic obstructive pulmonary disease (COPD).

These numbers are expected to continue to grow as the wheezo RPM program gains traction in the US, with a further 500 patients already identified for onboarding in the short term.

In reimagining healthcare across the entire patient journey, Health Industry HubTM is the only one-stop-hub bringing the diversity of Pharma, MedTech, Diagnostics & Biotech sectors together to inspire meaningful change.

The content on Health Industry Hub is copyright protected and should only be accessed under individual user licenses. To subscribe, please click here and visit T&Cs here.


News & Trends - MedTech & Diagnostics

Aussie medtech forges ahead, making inroads with new technology

Aussie medtech forges ahead, making inroads with new technology

Health Industry Hub | February 23, 2024 |

MedTech & Diagnostics News: Adelaide-based medical technology firm, LBT Innovations has successfully delivered its cutting-edge Automated Plate Assessment System (APAS) […]

More


News & Trends - Pharmaceuticals

Is the imposed PBS funding cap driving the migraine medicines shortage?

Is the imposed PBS funding cap driving the migraine medicines shortage?

Health Industry Hub | February 23, 2024 |

Pharma News: Australia finds itself grappling with an unparalleled shortage of migraine prevention medicines, leaving a significant impact on the […]

More


News & Trends - Pharmaceuticals

MSAC rejects Janssen's CAR T therapy despite clinical superiority, citing need for 'substantial price reduction'

MSAC rejects Janssen’s CAR T therapy despite clinical superiority, citing need for ‘substantial price reduction’

Health Industry Hub | February 23, 2024 |

Pharma News: The Medical Services Advisory Committee (MSAC) has deferred its decision on whether Janssen’s CAR T-cell therapy Carvykti (cilta-cel) […]

More


News & Trends - Pharmaceuticals

Gedeon Richter secures first endometriosis treatment in over a decade, with experts pushing for extension of NAPE

Gedeon Richter secures first endometriosis treatment in over a decade, with experts pushing for extension of NAPE

Health Industry Hub | February 23, 2024 |

Pharma News: The Therapeutic Goods Administration (TGA) has granted approval for the first endometriosis treatment in 13 years. Gedeon Richter […]

More


This content is copyright protected. Please subscribe to gain access.